DEVONIAN HEALTH GROUP INC.

 

PRESS RELEASE
For immediate release

 

DEVONIAN ANNOUNCES THE LISTING OF ITS SHARES ON THE TSX VENTURE
EXCHANGE

 

Québec, Québec, May 18, 2017 – Devonian Health Group Inc. (“Devonian” or the “Corporation”)
(TSX-V: GSD) is pleased to announce the receipt of the final bulletin from the TSX Venture
Exchange in connection with the completion of the previously announced qualifying transaction and
the concurrent public offering. Consequently, the subordinate voting shares of the Corporation will
began trading on the TSX Venture Exchange at the opening of markets on May 19, 2017 under the
symbol “GSD” and the common shares of Orletto will be delisted.

About Devonian

Devonian is a late stage botanical pharmaceutical company with novel therapeutic approaches
targeting unmet medical needs. Devonian’s core strategy is to develop prescription botanical drugs.
This strategy is supported by US-FDA set of regulatory guidelines favouring a more efficient drug
development pathway versus traditional prescription medicines. Devonian is based on a broad-based
platform originating from over ten years of research. This platform provides a unique process of
extraction, purification, stabilization and conditioning of a molecular complex responsible for the
photosynthetic process in plants and algae: The Supra Molecular Complex Extraction and
Stabilisation Technology (SUPREX). The “Thykaminetm” is the first product issued from this
platform. The potent anti-inflammatory and anti-oxidative activities of “Thykaminetm” have been
demonstrated in several pre-clinical experiments as well as in a Phase 2a ‘‘proof of concept’’ clinical
study in patients with mild-to-moderate distal ulcerative colitis. The product is now moving into
large phase 2 clinical trials in two therapeutic areas: Ulcerative Colitis and Atopic Dermatitis. While
the development of prescription botanical drugs is its core business, Devonian is also involved in the
development of high value derma-cosmeceutical products as part of a secondary strategy to generate
short-term revenues and optimize manufacturing efficiency.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in
policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this
release.

 

Contact:
André Boulet
President and Chief Executive Officer
Devonian Health Group inc.
Telephone: (514) 248-7509
Email: apboulet@groupedevonian.com